Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809757 · ClinicalTrials.gov registry record · Phase 3
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 197
- Enrollment target
NCT00809757 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 197 participants.
The verdict
NCT00809757, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 197 participants
- Enrollment target
Study Summary
A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to \<48 Months with Asthma.
Interventions
- DRUG Placebo
- DRUG Levalbuterol
- DRUG Levalbuterol UDV TID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809757
The ClinicalTrials.gov registry entry for NCT00809757 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00809757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809757 about?
NCT00809757 is a clinical study titled "A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma". A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to \<48 Months with Asthma.
What is the current status of trial NCT00809757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 197 participants. The study started on 2008-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00809757?
The interventions under investigation include: Placebo (DRUG), Levalbuterol (DRUG), Levalbuterol UDV TID (DRUG).
Who is sponsoring clinical trial NCT00809757?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.